10x Genomics Reports Sharply Reduced Q1 Net Loss, Improved Margins, and Key Legal Win
TXG has more than doubled off its 52-week low of $7.72.
Summary
10x Genomics reported a significantly reduced net loss and improved gross margin in Q1 2026, alongside strong product revenue growth and a favorable patent infringement ruling in Europe.
Key Events · Earnings and Guidance · TXG
-
Net Loss Significantly Reduced
The company reported a net loss of $13.5 million for Q1 2026, a substantial improvement from a net loss of $34.4 million in Q1 2025, reflecting strong cost management and operational efficiency.
-
Gross Margin Improvement
Gross margin increased to 70% in Q1 2026, up from 68% in the prior-year quarter, primarily due to lower inventory write-downs and reduced warranty costs.
-
Core Product Revenue Growth
Products and services revenue increased by 9% to $149.9 million, driven by a 13% increase in consumables revenue, with spatial consumables growing 31% year-over-year. Total revenue decreased 3% due to a non-recurring $16.8 million license revenue in Q1 2025.
-
Operating Expenses Cut
Total operating expenses decreased by 15% to $123.2 million, with research and development down 12% and selling, general and administrative expenses down 26%, demonstrating effective cost control.
Analysis · TXG · Industrial Applications And Services
This 10-Q filing details a strong operational quarter for 10x Genomics, building on the preliminary Q1 results announced in the recent 8-K. The company significantly narrowed its net loss by over 60% year-over-year, driven by substantial reductions in operating expenses and an improved gross margin. While total revenue saw a slight decline due to a non-recurring license payment in the prior year, core products and services revenue demonstrated healthy growth, particularly in spatial consumables. A notable legal victory, a permanent injunction against a competitor in Europe, reinforces the company's intellectual property position. The company maintains a robust cash position, providing ample liquidity for future operations and strategic initiatives. Investors should view these results as a positive indicator of operational efficiency and market strength in key product areas.
At the time of this filing, TXG was trading at $21.46 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $7.72 to $26.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.